Highlights Valeo Pharma Inc.

Equities

VPH

CA91915B1085

Delayed Toronto S.E. Other stock markets 07:48:33 16/05/2024 pm IST			5-day change	1st Jan Change
0.095 ^CAD	-5.00%		0.00%	-47.22%

25/04	Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call
22/03	Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valeo Pharma Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	15/03	CI
Valeo Pharma Brief: Notes Sagard credit facility amended to provide for early repayments and liquidity requirements in fiscal 2024	03/02	MT
Valeo Pharma Brief: Says Proceeds from reimbursement to be used for debt reduction purposes	03/02	MT
Valeo Pharma Brief: Adding SIMBRINZA remains under Valeo Pharma exclusive promotion and distribution	03/02	MT
Valeo Pharma Brief: Says Original commercialization and supply agreement amended following global divestment of XIIDRA	03/02	MT
Valeo Pharma Brief: Amending Agreement With Novartis Pharmaceuticals Canada For XIIDRA In Canada, and Credit Facility With Sagard Healthcare Royalty Partners, LP	03/02	MT
Valeo Pharma Amends Agreement with Novartis Pharmaceuticals Canada for (Pr)XIIDRA in Canada	03/02	CI
Valeo Pharma's Q4'23 Net Loss Holds Steady YOY	30/01	MT
Valeo Pharma Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	30/01	CI
Valeo Pharma Announces Organizational Changes and Cost Reduction Initiatives; Shares Jumped Near 30% Friday	20/11	MT
Valeo Pharma's Fiscal Q3 Loss Widens, Revenue Grows; Up 3.5%	14/23/14	MT
Valeo Pharma's Fiscal Q3 Loss Widens, Revenue Grows	14/23/14	MT
Valeo Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	14/23/14	CI
Valeo Pharma's Fiscal Q2 Loss Widens; Revenue Grows	14/23/14	MT
Valeo Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	14/23/14	CI
Valeo Pharma Edging Up After Providing Guidance of Record Revenues for Q2 2023	25/23/25	MT
Valeo Pharma Brief: Providing Guidance of Record Revenues for Q2 2023	25/23/25	MT
Valeo Pharma Inc. Provides Earnings Guidance for the Year 2023	27/23/27	CI
Valeo Pharma Brief: Reporting Fifth consecutive quarter of revenue growth at $13.2 million in Q1-23, up 210% over Q1-22; Fifth consecutive quarter of adjusted EBITDA loss reduction at $2.2 million, a 51% improvement over Q1-22	16/23/16	MT
North American Morning Briefing : Futures Deep in -2-	15/23/15	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Valeo Pharma Inc.

Equities

VPH

CA91915B1085

Highlights

Filters